真武汤加减联合达格列净与沙库巴曲缬沙坦治疗慢性心力衰竭的疗效OA
Efficacy of modified zhenwu decoction combined with dapagliflozin and sacubitril/valsartan in the treatment of chronic heart failure
目的 探索真武汤加减联合达格列净、沙库巴曲缬沙坦治疗慢性心力衰竭(CHF)的疗效.方法 选取巴彦淖尔市医院于2023年12月到2025年12月收治的90例CHF患者作为研究对象,随机分为对照组(达格列净联合沙库巴曲缬沙坦,n=45)和观察组(真武汤加减联合达格列净、沙库巴曲缬沙坦,n=45).对比两组的临床疗效、心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、脑钠肽(BNP)]、血清学指标[肌钙蛋白I(cTnI)、超敏C反应蛋白(hs-CRP)、醛固酮(ALD)]、生活质量(MLHFQ评分)以及不良反应.结果 与对照组相比,观察组临床总有效率明显更高[93.33%(42/45)vs.75.56%(34/45),P=0.020].治疗前,两组患者中医证候积分(P=0.578)、LVEF(P=0.766)、LVEDD(P=0.794)、LVESD(P=0.678)、BNP(P=0.722)、cTnI(P=0.705)、hs-CRP(P=0.769)、ALD(P=0.703)、MLHFQ评分(P=0.645)均无显著差异;治疗后,观察组LVEF显著高于对照组,中医证候积分、LVEDD、LVESD、BNP、cTnI、hs-CRP、ALD、MLHFQ评分显著低于对照组(P<0.001).两组不良反应发生率无显著差异[6.67%(3/45)vs.8.89%(4/45),P=0.694].结论 真武汤加减联合达格列净、沙库巴曲缬沙坦治疗慢性心力衰竭,可显著提升临床疗效,改善患者中医证候,优化心功能,降低血清心肌损伤及炎症相关指标,延长6 min步行距离(6MWT),提升生活质量,且安全性良好.
Objective To explore the efficacy of modified Zhenwu Decoction combined with dapagliflozin and sacubitril/valsartan in the treatment of chronic heart failure.Methods A total of 90 patients with CHF admitted to Baian Nur Hospital from December 2023 to December 2025 were selected as the research subjects.They were randomly divided into the control group(dapagliflozin combined with sacubitril/valsartan,n=45)and the observation group(modified Zhenwu Decoction combined with dapagliflozin and sacubitril/valsartan,n=45).The clinical efficacy,cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular diastolic end diameter(LVEDD),left ventricular systolic end diameter(LVESD),brain natriuretic peptide(BNP)],serumological indicators[cardiac troponin I(cTnI),high-sensitivity C-reactive protein(hs-CRP),aldosterone(ALD)],quality of life(MLHFQ score),and adverse reactions were compared between the two groups.Results Compared to the control group,the observation group exhibited a significantly higher clinical overall efficacy rate[93.33%(42/45)vs.75.56%(34/45),P=0.020].Before treatment,there was no significant difference in TCM syndrome scores(P=0.578),LVEF(P=0.766),LVEDD(P=0.794),LVESD(P=0.678),BNP(P=0.722),cTnI(P=0.705),hs-CRP(P=0.769),ALD(P=0.703),and MLHFQ score(P=0.645)between the two groups;after treatment,all the above indicators in both groups were significantly improved compared with those before treatment,and the LVEF of the observation group was significantly higher than that of the control group,and the TCM syndrome scores,LVEDD,LVESD,BNP,cTnI,hs-CRP,ALD,and MLHFQ score of the observation group were significantly lower than those of the control group(P<0.001).There was no significant difference in the incidence of adverse reactions between the two groups[6.67%(3/45)vs.8.89%(4/45),P=0.694].Conclusion Modified Zhenwu Decoction combined with dapagliflozin and sacubitril/valsartan for the treatment of chronic heart failure can significantly improve clinical efficacy,improve TCM syndrome,optimize cardiac function,reduce serum myocardial injury and inflammation-related indicators,prolong 6MWT,improve quality of life,and has good safety.
张慧;刘婧;马海仙;白雅琴
巴彦淖尔市医院,内蒙 巴彦淖尔 015000巴彦淖尔市医院,内蒙 巴彦淖尔 015000巴彦淖尔市医院,内蒙 巴彦淖尔 015000巴彦淖尔市医院,内蒙 巴彦淖尔 015000
慢性心力衰竭真武汤加减达格列净沙库巴曲缬沙坦
chronic heart failuremodified Zhenwu Decoctiondapagliflozin
《中华灾害救援医学》 2026 (4)
419-423,5
评论